Clinical trials: Klatskin's Tumor
Hilar Cholangiocarcinoma
Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
Hilar cholangiocarcinoma is a highly malignant tumor. Surgical resection or simple liver transplantation leads to poor prognosis accompanied by high recurrence rate and low survival rate.
- Trial name
- NCT02178280
- Testing
- liver transplantation combined with neoadjuvant therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hilar Cholangiocarcinoma, Duodenal Neoplasms
Diagnostic Accuracy of Eus Fnb in Difficult to Reach Lesions
The present study aims at comprehensively assessing the diagnostic performance and safety profile of EUS-FNB as a primary diagnostic tool for suspected malignancies in anatomically complex or deeply situated regions, including…
- Trial name
- NCT07621536
- Where
- Italy
- Volunteers
- 131 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cholangiocarcinoma, Tumor
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
In this study, we hope to evaluate the safety of PDT using temoporfin plus endoscopic stents in patients with inoperable bile duct cancers.
- Conditions
- Cholangiocarcinoma, Tumor, Klatskin Tumor
- Trial name
- PDT (NCT03003065)
- Testing
- Temoporfin
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Cholangiocarcinoma, Perihilar, Surgery
Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy and the second most common primary hepatic malignancy. The prognosis of CCA is dismal.
- Trial name
- NCT03383796
- Testing
- Three dimensional laparoscopic resection for pCCA, Open resection for pCCA
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc)
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)
In the POELH-II trial (Clinicaltrials.gov ID NCT05678218) patients with presumed resectable perihilar (pCCA), intrahepatic (iCCA) or mid-common bile duct (CBD) cholangiocarcinoma had the outcomes of their preoperative endoscopic…
- Conditions
- Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Perihilar Cholangiocarcinoma
- Trial name
- POELH-III (NCT07161869)
- Testing
- Registration of all findings during preoperative Endoscopic Ultrasound
- Where
- 6 sites in Netherlands
- Volunteers
- 250 people
- Sponsor
- Erasmus Medical Center
Cholangiocarcinoma, Interventional Imaging
Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma
The aim of the study is to evaluate the feasibility of irreversible electroporation in the treatment of locally advanced cholangiocarcinoma.
- Trial name
- HOPE (NCT04717687)
- Testing
- Irreversible electroporation
- Sponsor
- Poitiers University Hospital
Hilar Cholangiocarcinoma, Bile Duct Injury
Superior Bilioenteric Anastomosis by Magnetic Compressive Technique
The purpose of this study is to determine whether the magnetic compressive anastomosis has a better outcomes than traditional manual anastomosis on superior bilioenteric anastomosis.
- Conditions
- Hilar Cholangiocarcinoma, Bile Duct Injury, Choledochal Cyst, Biliary Calculi
- Trial name
- CTREG (NCT02801500)
- Testing
- Magnetic Compressive Anastomosis, Manual Anastomosis
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Bile Duct Obstruction, Klatskin's Tumor
Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture
The overall median survival of nonresectable malignant hilar obstruction in most series has been less than 6 months. Most patients with malignant hilar obstruction present with advanced disease, making palliative endoscopic…
- Trial name
- NCT01125865
- Testing
- SEMS insertion, DLS insertion
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Soon Chun Hyang University
Biliary Tract Cancer
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
- Trial name
- NCT06109779
- Testing
- Rilvegostomig, Capecitabine, Gemcitabine/Cisplatin
- Where
- 176 sites in United States, Australia and 19 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Jaundice, Obstructive, Klatskin Tumor
Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice
The purpose of this study is to evaluate the safety and effectiveness of different methods of preoperative biliary drainage in patients with extrahepatic bile duct neoplasms with obstructive jaundice (hilar cholangiocarcinoma…
- Trial name
- NCT03527875
- Testing
- PTBD group, ENBD group, EBS group
- Volunteers
- 564 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangitis
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar…
- Trial name
- NCT03104569
- Testing
- Injection of 37℃ contrast agent
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Among resectable biliary tract cancers (BTC) patients, surgery has historically been the standard treatment, but even with curative surgery, the cure rates remain relatively low, with most patients relapsing in the short term and…
- Trial name
- NCT06739252
- Testing
- Gemcitabine Oxaliplatin and 5FU
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Cholangiocarcinoma
A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma
This is a prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of a novel serological risk model on blood samples in early diagnosis of cholangiocarcinoma patients.
- Trial name
- NCT06658587
- Testing
- No interventions
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cholangiocarcinoma, Surgical Treatment
Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?
The investigators conducted a prospective study to determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in 138 patients with hilar cholangiocarcinoma.
- Conditions
- Cholangiocarcinoma, Surgical Treatment, Hepatectomy
- Trial name
- NCT00733200
- Testing
- Minor or Major Liver Resection
- Sponsor
- Huazhong University of Science and Technology
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
Unsatisfactory immediate outcomes of Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in surgery of cholangiocarcinoma suggested that patients with biliary cancer should not be treated by ALPPS.
- Trial name
- NCT03320980
- Testing
- RALPPS, portal vein embolization + major liver resection
- Volunteers
- 30 people
- Sponsor
- Moscow Clinical Scientific Center
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
This is an expanded access program (EAP) for eligible participants who do not qualify for participation in, or who are otherwise unable to access, the ongoing clinical trial ABC-108.
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT03414489
- Testing
- ABC294640
- Sponsor
- RedHill Biopharma Limited
Perihilar Cholangiocarcinoma
Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String
Prospective pilot study to assess the feasibility and efficacy of intrahepatic plastic biliary stents with a retrieval string in patients with presumed resectable perihilar cholangiocarcinoma requiring biliary drainage of the…
- Trial name
- CHORDA-II-p (NCT05874934)
- Testing
- Intrahepatic biliary stent with retrieval string
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
This phase I trial tests the safety, best dose, and effectiveness of NXP800 in treating patients with cholangiocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8
- Trial name
- NCT06420349
- Testing
- Biospecimen Collection, Computed Tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Hilar Cholangiocarcinoma
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma
The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.
- Trial name
- NCT03132649
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhujiang Hospital
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital